Journal of Clinical and Cellular Immunology
Open Access

Abstract

Increased Plasma Cells and Decreased B-cells in Tumor Infiltrating Lymphocytes are Associated with Worse Survival in Lung Adenocarcinomas

Hee Eun Lee, Lei Luo, Trynda Kroneman, Marie R Passow, Kristina M del Rosario, Michael R Christensen, Mary E Francis, John W O'Shaughnessy, Anthony J Blahnik, Ping Yang and Eunhee S Yi

Introduction: Clinical significance of tumor-infiltrating plasma cells and B-cells in lung adenocarcinoma is not well known.

Methods: CD3, CD20 and MUM1 immunostains were performed on representative tumor blocks selected from 120 consecutive lung adenocarcinoma cases treated by surgical resection at Mayo Clinic Rochester. CD3⁺ T-cells, CD20⁺ B-cells, and MUM1⁺ plasma cells were enumerated separately in the intraepithelial (IE) compartment and the stroma (ST) by digital image analyses using whole sections. Measured tumor-infiltrating plasma cells and B-cells were correlated with patient’s overall survival (OS) using Cox proportional hazards analysis.

Results: Median age of patients was 69 years (range, 46-91 years) and 52 were male. Median numbers (interquartile range) of CD20⁺ B-cells per 1mm² of tumor area (IE plus ST) and IE compartment within tumor area were 590 (224-1276) and 101 (38-109), respectively; the corresponding numbers of MUM1⁺ plasma cells were 298 (180-605), and 67 (22-145), respectively. The proportion of MUM1⁺ plasma cell among all TILs (MUM1⁺ cells/[CD3⁺ cells+CD20⁺ cells+MUM1⁺ cells] × 100) ranged 1%-59% (median13%) in the tumor area and showed a significant association with OS by univariate Cox analysis (negative correlation with hazard ratio (HR)=12.50 [95% confidence interval (CI), 1.75-89.27]). There was a significant association between IE CD20⁺ B-cells and the patient’s OS in univariate analysis (positive correlation with HR=0.81 [95% CI, 0.68-0.96]). Both parameters remained significant by multivariate analysis.

Conclusion: High plasma cell % among TILs in the tumor area and low IE B-cell count were associated with worse prognosis in lung adenocarcinoma patients.

Published Date: 2020-01-20; Received Date: 2019-12-27